UroGen Pharma Ltd.
UroGen Pharma Ltd. (NASDAQ: URGN) is trading at $41.35, about ₹3,970 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, up 0.29% today. Indian residents can buy UroGen Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$40.65
Today's high
$41.78
52 week low
$15.86
52 week high
$50.81
URGN opened at $41.47, closed previously at $41.23, and has traded between $15.86 and $50.81 over the past 52 weeks.
About
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Key statistics
Avg. volume
780.99K
Market cap
$2.01B
P/E Ratio
-20.88
Price-to-sales ratio
10.67
Enterprise value
$2.13B
Free cash flow yield
-7.90%
Debt-to-equity ratio
-1.48
Return on equity
81.78%
ROIC
-34.41%
Beta
1.58
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$109.79M
Earnings per share
-$3.19
Free cash flow
-$162.73M
Net profit margin
-51.73%
Gross margin
90.85%
EBITDA
-$135.66M
Revenue growth
21.45%
Similar securities
This is not an investment recommendation
How to buy UroGen Pharma from India
Indian residents can buy UroGen Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for UroGen Pharma and place an order
Find UroGen Pharma by name or by its ticker, URGN, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. UroGen Pharma trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your UroGen Pharma position in USD and INR. UroGen Pharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in UroGen Pharma from India
Trading and taxes when buying UroGen Pharma from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneUroGen Pharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy UroGen Pharma stock?
Yes. UroGen Pharma (URGN) has been listed on NASDAQ since 2017, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one UroGen Pharma share cost in rupees?
One UroGen Pharma share is $41.35 — about ₹3,970 at a USD/INR rate of 96.02 on 24 Sep 2026. Both the UroGen Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying UroGen Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of UroGen Pharma?
Yes. One UroGen Pharma share is $41.35, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in UroGen Pharma.
How are gains on UroGen Pharma shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the UroGen Pharma price. Paasa issues a capital-gains statement for your return.
Does UroGen Pharma pay a dividend?
No. UroGen Pharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade UroGen Pharma from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on UroGen Pharma shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare UroGen Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your UroGen Pharma holding, its cost and its closing value.
How do I sell UroGen Pharma and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.